Xvivo Perfusion AB (publ) (STO: XVIVO)
Sweden
· Delayed Price · Currency is SEK
533.00
+3.00 (0.57%)
Aug 30, 2024, 5:29 PM CET
Xvivo Perfusion AB Revenue
Xvivo Perfusion AB had revenue of 210.35M SEK in the quarter ending June 30, 2024, with 36.08% growth. This brings the company's revenue in the last twelve months to 698.73M, up 33.46% year-over-year. In the year 2023, Xvivo Perfusion AB had annual revenue of 597.54M with 43.88% growth.
Revenue (ttm)
698.73M
Revenue Growth
+33.46%
P/S Ratio
23.46
Revenue / Employee
4.60M
Employees
160
Market Cap
16.79B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 597.54M | 182.25M | 43.88% |
Dec 31, 2022 | 415.29M | 156.91M | 60.73% |
Dec 31, 2021 | 258.39M | 78.53M | 43.66% |
Dec 31, 2020 | 179.86M | -40.98M | -18.55% |
Dec 31, 2019 | 220.84M | 32.97M | 17.55% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca PLC | 520.76B |
Swedish Orphan Biovitrum AB (publ) | 23.71B |
Getinge AB (publ) | 33.33B |
Sectra AB (publ) | 3.04B |
Camurus AB (publ) | 1.59B |
Vitrolife AB (publ) | 3.54B |
Medicover AB (publ) | 21.70B |
Elekta AB (publ) | 18.12B |